Table 4.
Changes in quality of life from baseline at the first 3 months after discharge.
| EQ-5D-3L | Baselinea |
3-montha |
Comparisonc |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Controlb N = 60, n (%) | Interventionb N = 49, n (%) | Controlb N = 60, n (%) | Interventionb N = 49, n (%) | p1 | p2 | ||||||
| Mobility | No problems | 37 | (61.7) | 38 | (77.6) | 51 | (85.0) | 41 | (83.7) | 0.004 | 0.581 |
| Problems | 23 | (38.3) | 11 | (22.4) | 9 | (15.0) | 8 | (16.3) | |||
| Self-care | No problems | 50 | (83.3) | 43 | (87.8) | 55 | (91.7) | 47 | (93.9) | 0.227 | 0.289 |
| Problems | 10 | (16.7) | 6 | (12.2) | 5 | (8.3) | 2 | (4.1) | |||
| Usual activities | No problems | 46 | (76.7) | 41 | (83.7) | 55 | (91.7) | 46 | (93.9) | 0.049 | 0.180 |
| Problems | 14 | (23.3) | 8 | (16.3) | 5 | (8.3) | 3 | (6.1) | |||
| Pain/discomfort | No problems | 37 | (61.7) | 34 | (69.4) | 38 | (63.3) | 36 | (73.5) | 1.000 | 0.832 |
| Problems | 23 | (38.3) | 15 | (30.6) | 22 | (36.7) | 13 | (26.5) | |||
| Anxiety/depression | No problems | 35 | (58.3) | 30 | (61.2) | 45 | (75.0) | 36 | (73.5) | 0.052 | 0.238 |
| Problems | 25 | (41.7) | 19 | (38.8) | 15 | (25.0) | 13 | (26.5) | |||
| EQ-5D-3L index value, median (IQR) | 0.686 | (0546.; 1) | 0.766 | (0.645; 1) | 1 | (0.726; 1) | 1 | (0.726; 1) | <0.001d | 0.004d | |
| Change of EQ-5D-3L index values, median (IQR) | NA | NA | 0.234 | (0.000; 0.379) | 0.000 | (0.000; 0.275) | p3 = 0.081 | ||||
Abbreviations: EQ-5D-3L, the European Quality of Life Questionnaire - 5 Dimensions - 3 Levels; IQR, interquartile range, NA, not applicable. p1 Comparison between baseline and 3-month EQ-5D-3L scores of the control group. p2 Comparison between baseline and 3-month EQ-5D-3L scores of the intervention group. p3 Comparison between changes from baseline of EQ-5D-3L index values of the control and intervention groups at the first 3 months after discharge. aNo difference in each dimension and index value of EQ-5D-3L between control and intervention groups at baseline or the first 3 months after discharge. bSample size of patients who reported EQ-5D-3L at both baseline and the first 3 months after discharge. cUsing McNemar test if other tests were not mentioned. dUsing Wilcoxon signed rank test.